|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, serum levels of the carbohydrate antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) were determined preoperatively in 364 breast cancer patients with no clinical signs of metastasis.
|
11553856 |
2001 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of CEA and CA153 were all significantly higher in preoperative BC compared with those in HC (P = 0.008 and P = 0.001, respectively), and only the level of CA153 decreased in postoperative BC compared with preoperative BC (P = 0.015).
|
23389917 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is an important oncomarker for the detection of breast cancer.
|
31247453 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that CEA and CA15-3 levels might be useful for predicting the prognosis of patients with operable early breast cancer irrespective of the subtype.
|
29433529 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Their low sensitivity and specificity preclude the use of serum markers such as the MUC-1 mucin glycoproteins (CA 15.3, BR 27.29) and carcinoembryonic antigen in the diagnosis of early breast cancer.
|
16254457 |
2005 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide.
|
26892612 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the antitumor potential of a novel viral agent, an attenuated strain of measles virus deriving from the Edmonston vaccine lineage, genetically engineered to produce carcinoembryonic antigen (CEA) against breast cancer.
|
16642271 |
2006 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Since breast carcinomas, especially in situ carcinomas, express CEA, this finding may suggest a heretofore unappreciated relationship between myoepithelial cells and breast cancer.
|
10564638 |
1999 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We examined the usefulness of the TRC test with a double marker, cytokeratin 19 (CK19) and carcinoembryonic antigen (CEA) mRNA, to detect sentinel lymph nodes (SLN) metastasis in breast cancer patients.
|
22782345 |
2012 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CEA in 202 Stages I and II breast carcinomas was assessed by immunohistochemistry, and the results were correlated with various histologic and clinical parameters to establish CEA's biologic relevance.
|
7914825 |
1994 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While CK-18 is a marker for epithelia in general, CEA is mainly employed in the detection of gastrointestinal and breast carcinomas.
|
7541767 |
1995 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At 90% specificity of the assay (CEA, 2.13 ng/mg protein), the corresponding sensitivity for breast cancer detection was 62%, according to the receiver operating characteristic curve drawn.
|
15508191 |
2004 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic Value of Serum Concentration and Integrity of Circulating Cell-Free DNA in Breast Cancer: A Comparative Study With CEA and CA15-3.
|
29701836 |
2018 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression.
|
23525470 |
2013 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
With clinical implications, p16 hypermethylation in plasma and/or raised serum CEA levels may prove useful as diagnostic and prognostic markers for breast cancer.
|
14534701 |
2004 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, preoperative CEA and CA15-3 serum levels were evaluated in the prediction of the prognosis for young patients with breast cancer.
|
30214602 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with high levels of CTC double-marked by KRT19 and CEACAM5 mRNA had shorter DMFS (P < 0.0001) and OS (P = 0.016) for patients with breast cancer.
|
30535933 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although expression of CEA largely ceases prior to birth, several human epithelial cancers, including colorectal, gastric, squamous esophageal, and breast carcinomas have been known to overexpress CEA, suggesting its potential as an immunotherapeutic target.
|
30666318 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
|
20586026 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Authors investigated the expression level of miRNAs (miRNA-21, miRNA-126, and miRNA-155) to evaluate their role as diagnostic and prognostic markers for breast cancer compared with other commonly used protein-based markers (CEA and CA15-3).
|
30825229 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the tumor markers currently available for breast cancer detection include carcinoembryonic antigen (CEA), carbohydrate antigen 15.3 (CA15.3), and carbohydrate antigen 27.29 (CA27.29) exhibited certain limitations.
|
19787229 |
2009 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors.
|
28228086 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of c-erbB-2 protein in stages I-IIIB breast cancer was associated with histological grade and serum CEA level, but not with other clinicopathological factors.
|
9544822 |
1998 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is one of the tumor markers available for evaluating disease progression status after initial therapy and monitoring subsequent treatment modalities in colorectal, gastrointestinal, lung, and breast carcinoma.
|
29611386 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While miR-34a provides valuable information for diagnosis and staging, combination with tumor markers CA15-3 or CEA improves the sensitivity for breast cancer detection.
|
29854296 |
2018 |